FOXO3a and the MAPK p38 are activated by cetuximab to induce cell death and inhibit cell proliferation and their expression predicts cetuximab efficacy in colorectal cancer

BACKGROUND: Cetuximab, a monoclonal antibody against EGFR used for the treatment of colorectal cancer (CRC), is ineffective in many patients. The aim of this study was to identify the signalling pathways activated by cetuximab in CRC cells and define new biomarker of response. METHODS: We used in vi...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Br J Cancer
Main Authors: Marzi, L, Combes, E, Vié, N, Ayrolles-Torro, A, Tosi, D, Desigaud, D, Perez-Gracia, E, Larbouret, C, Montagut, C, Iglesias, M, Jarlier, M, Denis, V, Linares, L K, Lam, E W-F, Martineau, P, Del Rio, M, Gongora, C
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group 2016
Assuntos:
Translational Therapeutics
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5104890/
https://ncbi.nlm.nih.gov/pubmed/27685445
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2016.313
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados